

BRANCH OUT

Volume 8, No 4

Fall 2006

Message from the President

Mike LeBlanc

In This Issue

- Message from the President
- Human Cell Lines in Pharmaceuticals
- Membership Awards
- 10 –year Anniversary Celebration
- New Executive and Committee Chairs

It has been a while since I've been able to find the time to update you on the activities of our branch executive. Once again, I had the privilege of representing our branch at the CSHP National AGM in Montreal. After 3 days of meetings and 4 days of the conference, I was exhausted and ready for a nap. Fortunately I took some notes to highlight for you.

- Our advocacy themes for the coming 2-3 years will be
 - "Medication Safety" focus on safe use of medications and the need for better distributive and clinical services, including use of bar codes and medication reconciliation
 - "Scope of Practice" focus on pharmacists prescribing, primary health care, use of technicians -
- A new "Pharmacy Awareness Week" brochure and promotional material with a focus on hospital practice were prepared by the summer student and presented at Issues Day for feedback.
- The ASHP 2015 initiative was Canadianized and we have adopted "CSHP 2015"
 - This is a long-term vision of what pharmacy practice should look like in 10 years. It is a huge undertaking and an initiative that will directly affect all of us in our daily practice.
 - Those of you unfamiliar with the American document can access it at <http://www.ashp.org/2015/>.
 - If you have questions or would like to see the Canadian version, please feel free to contact me.
- National continues to examine the concept of provision of CE to its members via online or web-based media
 - For example, having slides/audio of AGM or PPC presenters available to members, or enlisting the services of an existing online CE provider (such as rxbriefcase) to develop hospital practice oriented continuing education.

As you can see the meetings were filled with exciting news and activities and, as usual, gave me new energy to bring home.

(Cont on pg 5)

Vision 2006

*"A Revitalized Society...The influential voice for hospital pharmacy...
Inspiring and Supporting our Members"*

Use of Human Cell Lines in Pharmaceuticals

By: Dr. John Hawboldt, MUN School of Pharmacy

Various commercially available pharmaceutical products are derived from or cultivated on fetal cells lines that were obtained from abortions.¹⁻¹⁷ Fetal cell lines (human diploid material) are used to produce the vaccines. The isolation and characterization of human diploid cell strains from fetal tissue make this type of cell available as a substrate for the production of live virus vaccines. The cell lines are used repeatedly to produce vaccine until, due to the natural process of aging, they are no longer able to act as a substrate for vaccine production. New human cell lines must then be obtained from abortions or other sources to replace those that have naturally aged.

The cell strains mentioned below were derived from the lung, and kidney of separate, elective abortions.^{14,17} Some of our patients may have a biological, ethical or religious objection to products that come from human sources. The chart below allows us to provide information to patients to make informed decisions. It also makes known the fact the alternatives are available in other countries.

Disease	Drug Name	Manufacturer	Cell Line (Fetal)	Alternative (Drug/Manufacturer /Source)
Chickenpox	Varilrix ®	GSK	MRC-5	None Available
	Varivax®	Merck & Co	WI-38, MRC-5	
Hepatitis A	Epaxal®	Berna Biotech	MRC-5	Aimmungen®
	Havrix ®	GSK	MRC-5	Kaketsuken
	Vaqta ®	Merck & Co	MRC-5	Vero (monkey)
	Avaxim ®	Sanofi Pasteur	MRC-5	Available in Japan and Europe
	Avaxim Pediatric ®	Sanofi Pasteur	MRC-5	
Hepatitis A and Typhoid Fever	Vivaxim ®	Sanofi Pasteur	MRC-5	As above for Hep A component
Hepatitis A & B	Twinrix ® (Hep A Component)	GSK	MRC-5	As above for Hep A component, Hep B is derived from yeast

(Cont on Page 3)

Winners of the Early Bird Membership Draws

- 1 Complimentary Membership: Brad Payne
- 2 awards of \$150: Randy McFayden, Pamela Rudkin
- 3 awards of \$100: Lisa Bishop, Kristi Parmiter, Barb Thomas
- 3 awards of \$50: Esther D'Souza, Lorainne Snow, Ted Dawe



“A Revitalized Society...The influential voice for hospital pharmacy... Inspiring and Supporting our Members”

(Cont from Page 2)

Disease	Drug Name	Manufacturer	Cell Line (Fetal)	Alternative (Drug/Manufacturer /Source)
Measles, Mumps, Rubella	Priorix ® MMR II ®	GSK Merck & Co	MRC-5 RA27/3, WI-38	Attenuvax® (Measles) Merck Chick embryo Available in US Mumpsvax ® (Mumps) Merck Chick embryo Available in US Takahashi (Rubella) Kitasato Institute Rabbit Available in Japan and Europe
MMR + Chicken-pox	ProQuad ®	Merck & Co.	RA27/3, WI-38, MRC-5	None Available
Polio	Inactivated Polio-myelitis Vaccine – IPV ® Pentacel ® Quadracel ® Td Polio Ad-sorbed ®	Sanofi Pasteur	MRC-5	Infanrix-IPV & IPV/Hib® GSK Non-human source Available in Europe and Australia Pentacel®
Rabies	Imovax ®	Sanofi Pasteur	MRC-5	Rabavert® Chiron Chick Embryo Available in Canada
Rheumatoid Arthritis	Enbrel ®	Immunex (Amgen)	WI-26 VA4	None Available
Sepsis	Xigris ®	Eli Lilly	HEK-293	None Available

NOTE: -All flu vaccines use non-human cell lines

-Immune-Globulin shots will provide temporary immunity (3-5 months) for Hepatitis-A and Rubella



Cont on Page 5

*“A Revitalized Society...The influential voice for hospital pharmacy...
Inspiring and Supporting our Members”*

**Don't forget the celebration of our
10-year anniversary as a Branch of CSHP!**

All current and past CSHP members are invited to share in our 10-year anniversary celebration as a Branch of CSHP. We will hold our celebration during PANL's annual conference on Friday, Sept 29th. Our annual general meeting will be help from 6-7pm, and the anniversary celebration and awards presentation will be held from 8:30 to 9:30.

For more information please visit www.cshp-nl.com or contact Lisa Bishop at ldbishop@mun.ca. A detailed schedule of events for the PANL conference and the registration form can be found on PANL's website (www.panl.net).



People

**Congratulations to Kristi Parmiter & Randy McFadyen on the arrival of their Baby Girl,
Ally!!!**

Executive and Committee Chairs 2006-7

Executive

President: Mike LeBlanc
 President-elect: Leslie Phillips
 Delegate: Pamela Rudkin
 Secretary: Amy Conway
 Treasurer: Tanya O'Brien
 Senior Advisor: Lisa Bishop
 Student Representative: Erin Schwenger

Committee Chairs

Membership Committee: John Hawboldt
 Newsletter Committee: Renelle Bishop
 Awards Committee: Barbara Thomas
 Website Committee: David Smith
 Education Committee: Rick Abbott
 Nominating Committee: Leslie Phillips
 Advocacy Representative: Stephanie Young



(Cont from pg 1)

At our branch, we have already held our Student Welcoming session, which was a great success thanks to the efforts of our new student representative Erin Schwenger and our membership committee (John Hawboldt and Lisa Bishop). Don't forget, your order for your membership renewal books should be in by October 2.

We have also been active advocating on behalf of the hospital pharmacists in NL and our current concerns with the shortage of pharmacists. Dr. Elizabeth Kozyra communicated our concerns with the crisis and the adverse effect it could have on patient safety and outcomes. There was also a letter to the editor of the Telegram discussing the fact that the issues are not solely monetary and that job satisfaction is equally important. More recently, CSHP and PANL members came together to create a document to submit to government that outlined the issues and identified possible solutions. We are starting to hear rumblings of some results, so keep your fingers crossed.

Hopefully I'll see you all at the AGM when we unveil 2 new awards and celebrate 10 years of CSHP-NL.

As always, if you would like clarification or would like to speak to me directly, I can be reached by email (Michael.LeBlanc@easternhealth.ca) or phone (777-7546).

Mike

(Cont from Page 3)

References:

1. Varilrix Product Monograph. GlaxoSmithKline Inc. http://www.gsk.ca/en/products/vaccines/varilrix_pm.pdf. Accessed March 14, 2006.
2. Varivax. Product Monograph. Merck. http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Accessed March 14, 2006.
3. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Supplementary Statement On Hepatitis A Vaccine (Acs-4). <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/00vol26/26sup/acs4.html>. Accessed March 14, 2006.
4. Vaqta Product Monograph. Merck. http://www.merck.com/product/usa/pi_circulars/v/vaqta/vaqta_pi.pdf Accessed March 14, 2006.
5. Havrix. Product Monograph. GlaxoSmithKline Inc. http://www.gsk.ca/en/products/vaccines/havrix_pm.pdf. Accessed March 14, 2006.
6. Priorix Product Monograph. GlaxoSmithKline Inc. http://www.gsk.ca/en/products/vaccines/priorix_pm.pdf. Accessed March 14, 2006.
7. MMR II Product Monograph. Merck. http://www.merckfrosst.ca/e/products/monographs/M-M-R_II-756-a_3_02-E.pdf. Accessed March 14, 2006.
8. ProQuad Product Monograph. Merck. http://www.merck.com/product/usa/pi_circulars/p/proquad/proquad_pi.pdf. Accessed March 14, 2006.
9. IPV Product Monograph. http://www.vaccineshoppecanada.com/secure/pdfs/ca/ipv_E.pdf. Accessed March 14, 2006.
10. Imovax Product Monograph. http://198.73.159.214/statics/vaccines/english/IMOVAX_E.pdf. Accessed March 14, 2006.
11. Enbrel. United States Patent. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahmtl/srchnum.htm&r=1&f=G&l=50&s1=5,712,155.WKU.&OS=PN/5,712,155&RS=PN/5,712,155>. Accessed March 14, 2006.
12. Vaccines And Related Biological Products Advisory Committee. United States Of America Food And Drug Administration Center For Biologics Evaluation And Research. <http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3750t1.rtf>. Accessed March 14, 2006.
13. Jacobs JP, et al. Characteristics of a human diploid cell designated MRC-5. *Nature*. 1970;227(5254):168-70.
14. Plotkin SA, Cornfield D, Ingalls TH. Studies of Immunization with living rubella virus: Trials in children with a strain cultured from an aborted fetus. *Am J Dis Child*.1965;110: 381-389.
15. Plotkin S, et. al. Attenuation of RA27/3 Rubella Virus in WI-38 Human Diploid Cells. *Am J Dis Child*.1969;118:178-185.
16. Weibel RE, et al. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. *Proc Soc Exp Biol Med*. 1980;165(2):323-326.
17. Hayflick L, et al. The serial cultivation of human diploid cell strains. *Exp Cell Res*. 1961;25:585-621.

Don't forget to choose your complimentary
CSHP Membership Educational Resources
by Oct 2nd!! See our Branch Website for details

Contact John Hawboldt @ hawboldt@mun.ca or 777-8777 with your choice.



The Canadian Society of Hospital Pharmacists assumes no responsibility for the statements and opinions advanced by contributors to the Branch Out. Views expressed in the editorials are those of the authors and do not necessarily represent the official position of the Canadian Society of Hospital Pharmacists.

Vision 2006

*"A Revitalized Society...The influential voice for hospital pharmacy...
Inspiring and Supporting our Members"*